Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

Last updated: September 16, 2025
Sponsor: Luxembourg Institute of Health
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gastrointestinal Diseases And Disorders

Treatment

All participants will be asked to provide data and samples for collection and analysis.

Clinical Study ID

NCT05733702
LUX-CLIN-001
  • Ages > 18
  • All Genders

Study Summary

This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change.

At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol.

The mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data.

The main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥ 18 years old

  • Participants are willing and able to comply with the protocol including undergoingdata and sample collection as well as study visits and examinations.

  • Signed informed consent form

  • Diagnosed with Inflammatory bowel disease, either Crohn's disease or ulcerativecolitis, at least 3 months before the enrolment AND occurrence of a significantchange in the treatment of the disease (either change of drug dosage OR change ofmedication within the same treatment class OR change of treatment class OR additionof a drug to a treatment regimen already ongoing). A change of drug dosage orfrequency is considered significant if it fulfills the requirements in section 7.1Note: Patients with ostomy or with short bowel syndrome can be included if theyfulfill all the eligibility criteria

Exclusion

Exclusion Criteria:

  • Any condition that could potentially hamper the compliance with the study protocol,including study procedures and study visits (such as mental disability that makes itdifficult or impossible to answer questionnaires)

  • Not fluent in any of the following languages: French, English or German

  • Known pregnancy

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: All participants will be asked to provide data and samples for collection and analysis.
Phase:
Study Start date:
February 01, 2024
Estimated Completion Date:
November 30, 2029

Study Description

Due to the complexity and heterogeneity of IBD, personalized treatment should be implemented in the management of patients.

In particular, the patient stratification by their predicted response to different drugs and the stratification of patients by predicted disease course, which might result in the use of more or less aggressive treatment approaches, are the major unmet clinical needs that should be addressed.

In this context, key unmet needs that can be addressed by data science and Artificial Intelligence (AI) include:

  1. Identification of predictive biomarkers for drug response estimation and identification of prognostic biomarkers to estimate the future course of the disease, focusing on patients in whom treatment needs to be changed.

  2. Improved monitoring of patient well-being.

Patients deemed eligible for the study will be asked to provide data and samples for collection and analysis. They will be followed up for a maximum of 5 years starting from the date of inclusion.

During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months and at 12 months. Patient Reported Outcomes (PROs), including voice recording will be collected optionally at different time points using the Colive smartphone app while physical activity and quality of sleep will be monitored optionally via a smartwatch.

Additionally, participants will be asked to provide biological samples and imaging data (if performed as per standard of care) at different time points (baseline; 3 months; 12 months).

A long-term Follow-up (FU) (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected on a yearly basis, and PROs are collected every 6 months.

Connect with a study center

  • Centre Hospitalier de Luxembourg (CHL)

    Luxembourg, L-1210
    Luxembourg

    Site Not Available

  • Centre Hospitalier de Luxembourg (CHL)

    Luxembourg 2960316, L-1210
    Luxembourg

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.